Down-regulation of HLA II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients

Cancer Immunology, Immunotherapy

Volumn 53, Issue 6, 2004, Pages 551-559

  Ugurel, Selma ^a,b   Uhlig, Dario ^c   Pföhler, Claudia ^c   Tilgen, Wolfgang ^c   Schadendorf, Dirk ^a,b   Reinhold, Uwe ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

CD11c; CD71; CD80 B7 1; CD86 B7 2; HLA class I; HLA class II; Melanoma; Monocytes

Indexed keywords

ALPHA INTERFERON; CD14 ANTIGEN; CD71 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; CISPLATIN; DACARBAZINE; GLYCOPROTEIN P 15095; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOMODULATING AGENT; TEMOZOLOMIDE; VINDESINE;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD; ANTIGENS, CD11C; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOCYTES; NEOPLASM STAGING; RECEPTORS, TRANSFERRIN; SKIN NEOPLASMS;

EID: 2542471742     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0489-1     Document Type: Article

References (34)

1. American Joint Committee on Cancer (1997) Staging manual, 5th edn. Lippincott, Philadelphia, p 143
2. Ardavin C, Martinez del Hoyo G, Martin P, Anjuere F, Arias CF, Marin AR, Ruiz S, Parrillas V, Hernandez H (2001) Origin and differentiation of dendritic cells. Trends Immunol 22:691-700
3. Becker JC, Czerny C, Bröcker EB (1994) Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol 6:1605-1612
4. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buetnner R (1997) Melanoma-inhibitory activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149-3153
5. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY (1997) The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 18:493-497
6. Ditschkowski M, Kreuzfelder E, Rebmann V, Ferencik S, Majetschak M, Schmid EN, Obertacke U, Hirche H, Schade UF, Grosse-Wilde H (1999) HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg 229:246-254
7. Fidler IJ, Kleinerman ES (1984) Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol 2:937-943
8. Fidler IJ, Schroit AJ (1988) Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta 948:151-173
9. Filaci G, Contini P, Brenci S, Lanza L, Scudeletti M, Indiveri F, Puppo F (1995) Increased serum concentration of soluble HLA-DR antigens in HIV infection and following transplantation. Tissue Antigens 46:117-123
10. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3:483-490
11. Gebhard B, Gnant M, Schutz G, Roka S, Weigel G, Kandioler D, Taucher S, Grunberger T, Roth E, Jakesz R, Spittler A (2000) Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast. Anticancer Res 20:4599-4604
12. Girndt M, Sester M, Sester U, Kaul H, Kohler H (2001) Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 59:1382-1389
13. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA (1999) Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189:1343-1354
14. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D (1995) Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 31A:924-928
15. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (1992) CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607-609
16. Houghton AN, Gold JS, Blachere NE (2001) Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 13:134-140
17. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965
18. Kleinerman ES, Ceccorulli LM, Bonvini E, Zicht R, Gallin JI (1985) Lysis of tumor cells by human blood monocytes by a mechanism independent of activation of the oxidative burst. Cancer Res 45:2058-2064
19. Lenschow DJ, Sperling AI, Cooke MP, Freeman G, Rhee L, Decker DC, Gray G, Nadler LM, Goodnow CC, Bluestone JA (1994) Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol 153:1990-1997
20. Matsuoka T, Tabata H, Matsushita S (2001) Monocytes are differentially activated through HLA-DR, -DQ, and -DP molecules via mitogen-activated protein kinases. J Immunol 166:2202-2208
21. Novellino PS, Trejo YG, Beviacqua M, Bordenave RH, Rumi LS (1999) Cisplatin containing chemotherapy influences HLA-DR expression on monocytes from cancer patients. J Exp Clin Cancer Res 18:481-484
22. Novellino PS, Trejo YG, Beviacqua M, Bordenave RH, Rumi LS (2000) Regulation of HLA-DR antigen in monocytes from colorectal cancer patients by in vitro treatment with human recombinant interferon-gamma. J Investig Allergol Clin Immunol 10:90-93
23. Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H (2002) Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer 100:580-585
24. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380-384
25. Roth MD, Gitlitz BJ, Kiertscher SM, Park AN, Mendenhall M, Moldawer N, Figlin RA (2000) Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res 60:1934-1941
26. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19:577-583
27. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 7:1282-1286
28. van Bokhorst-de van der Schuer MA, von Blomberg-van der Flier BM, Riezebos RK, Scholten PE, Quak JJ, Snow GB, van Leeuwen PA (1998) Differences in immune status between well-nourished and malnourished head and neck cancer patients. Clin Nutr 17:107-111
29. van Bokhorst-de van der S, von Blomberg-van der Flier BM, Kuik DJ, Scholten PE, Siroen MP, Snow GB, Quak JJ, van Leeuwen PA (2000) Survival of malnourished head and neck cancer patients can be predicted by human leukocyte antigen-DR expression and interleukin-6/tumor necrosis factor-alpha response of the monocyte. JPEN J Parenter Enteral Nutr 24:329-336
30. Van Gool SW, Vandenberghe P, de Boer M, Ceuppens JL (1996) CD80, CD86, and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev 153:47-83
31. Wahl SM, McCartney-Francis N, Mergenhagen SE (1989) Inflammatory and immunomodulatory roles of TGF-beta. Immunol Today 10:258-261
32. Williams MA, Withington S, Newland AC, Kelsey SM (1998) Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. J Infect Dis 178:1421-1433
33. Woiciechowsky C, Asadullah K, Nestler D, Schoning B, Glockner F, Docke WD, Volk HD (1998) Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: effect of tumor extirpation. J Neuroimmunol 84:164-171
34. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433